These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 28612141)

  • 1. Deterministic identifiability of population pharmacokinetic and pharmacokinetic-pharmacodynamic models.
    Siripuram VK; Wright DFB; Barclay ML; Duffull SB
    J Pharmacokinet Pharmacodyn; 2017 Oct; 44(5):415-423. PubMed ID: 28612141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A general model-based design of experiments approach to achieve practical identifiability of pharmacokinetic and pharmacodynamic models.
    Galvanin F; Ballan CC; Barolo M; Bezzo F
    J Pharmacokinet Pharmacodyn; 2013 Aug; 40(4):451-67. PubMed ID: 23733369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global identifiability of linear compartmental models--a computer algebra algorithm.
    Audoly S; D'Angiò L; Saccomani MP; Cobelli C
    IEEE Trans Biomed Eng; 1998 Jan; 45(1):36-47. PubMed ID: 9444838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What do we mean by identifiability in mixed effects models?
    Lavielle M; Aarons L
    J Pharmacokinet Pharmacodyn; 2016 Feb; 43(1):111-22. PubMed ID: 26660913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parameter identifiability and estimation of HIV/AIDS dynamic models.
    Wu H; Zhu H; Miao H; Perelson AS
    Bull Math Biol; 2008 Apr; 70(3):785-99. PubMed ID: 18247096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal experimental requirements for structural identifiability in linear compartmental models. The software 'IDEXMIN'.
    Mérino JA; de Biasi J; Plusquellec Y; Houin G
    Arzneimittelforschung; 1996 Mar; 46(3):324-8. PubMed ID: 8901159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics.
    Gibiansky L; Gibiansky E
    Expert Opin Drug Metab Toxicol; 2009 Jul; 5(7):803-12. PubMed ID: 19505189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Local identifiability and sensitivity analysis of neuromuscular blockade and depth of hypnosis models.
    Silva MM; Lemos JM; Coito A; Costa BA; Wigren T; Mendonça T
    Comput Methods Programs Biomed; 2014; 113(1):23-36. PubMed ID: 24252467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An approach for identifiability of population pharmacokinetic-pharmacodynamic models.
    Shivva V; Korell J; Tucker IG; Duffull SB
    CPT Pharmacometrics Syst Pharmacol; 2013 Jun; 2(6):e49. PubMed ID: 23887745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parameter Identifiability of Fundamental Pharmacodynamic Models.
    Janzén DL; Bergenholm L; Jirstrand M; Parkinson J; Yates J; Evans ND; Chappell MJ
    Front Physiol; 2016; 7():590. PubMed ID: 27994553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The deterministic identifiability of nonlinear pharmacokinetic models.
    Godfrey KR; Fitch WR
    J Pharmacokinet Biopharm; 1984 Apr; 12(2):177-91. PubMed ID: 6491900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifiability and interval identifiability of mammillary and catenary compartmental models with some known rate constants.
    Vicini P; Su H; DiStefano JJ
    Math Biosci; 2000 Oct; 167(2):145-61. PubMed ID: 10998486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calculating all multiple parameter solutions of ODE models to avoid biological misinterpretations.
    Saccomani MP; Thomaseth K
    Math Biosci Eng; 2019 Jul; 16(6):6438-6453. PubMed ID: 31698571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review: To be or not to be an identifiable model. Is this a relevant question in animal science modelling?
    Muñoz-Tamayo R; Puillet L; Daniel JB; Sauvant D; Martin O; Taghipoor M; Blavy P
    Animal; 2018 Apr; 12(4):701-712. PubMed ID: 29096725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural identifiability analysis and reparameterisation (parameter reduction) of a cardiovascular feedback model.
    Cheung SY; Majid O; Yates JW; Aarons L
    Eur J Pharm Sci; 2012 Jul; 46(4):259-71. PubMed ID: 22343490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural identifiability analyses of candidate models for in vitro Pitavastatin hepatic uptake.
    Grandjean TR; Chappell MJ; Yates JW; Evans ND
    Comput Methods Programs Biomed; 2014 May; 114(3):e60-9. PubMed ID: 23870173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural identifiability of physiologically based pharmacokinetic models.
    Yates JW
    J Pharmacokinet Pharmacodyn; 2006 Aug; 33(4):421-39. PubMed ID: 16568353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A confidence building exercise in data and identifiability: Modeling cancer chemotherapy as a case study.
    Eisenberg MC; Jain HV
    J Theor Biol; 2017 Oct; 431():63-78. PubMed ID: 28733187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal design for multiresponse pharmacokinetic-pharmacodynamic models - dealing with unbalanced designs.
    Ogungbenro K; Gueorguieva I; Majid O; Graham G; Aarons L
    J Pharmacokinet Pharmacodyn; 2007 Jun; 34(3):313-31. PubMed ID: 17285361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of IPPSE, an alternative method for sequential population PKPD analysis.
    Lacroix BD; Friberg LE; Karlsson MO
    J Pharmacokinet Pharmacodyn; 2012 Apr; 39(2):177-93. PubMed ID: 22270323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.